http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 12:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html <p align="justify">BROSSARD, Quebec, June 18, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, announces its intention to settle two (2) arm’s-length demand loans in the aggregate amount of C$125,000 by the issuance of an aggregate number of 625,000 common shares of the Corporation (each a “Share”) at an issue price of C$0,20 per Share. The Corporation is proposing to issue the Shares in order to preserve its cash.</p> <p align="justify">The agreements http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html Thu, 18 Jun 2026 12:00:00 -0400 4D4A ADK DGNOF O.02535360 http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html <p align="justify">BROSSARD, Quebec, June 18, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, announces its intention to settle two (2) arm’s-length demand loans in the aggregate amount of C$125,000 by the issuance of an aggregate number of 625,000 common shares of the Corporation (each a “Share”) at an issue price of C$0,20 per Share. The Corporation is proposing to issue the Shares in order to preserve its cash.</p> <p align="justify">The agreements http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html Thu, 18 Jun 2026 12:00:00 -0400 4D4A ADK DGNOF O.02535360 http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html <p align="justify">BROSSARD, Quebec, June 18, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, announces its intention to settle two (2) arm’s-length demand loans in the aggregate amount of C$125,000 by the issuance of an aggregate number of 625,000 common shares of the Corporation (each a “Share”) at an issue price of C$0,20 per Share. The Corporation is proposing to issue the Shares in order to preserve its cash.</p> <p align="justify">The agreements http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html Thu, 18 Jun 2026 12:00:00 -0400 4D4A ADK DGNOF O.02535360 http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html <p align="justify">BROSSARD, Quebec, June 18, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, announces its intention to settle two (2) arm’s-length demand loans in the aggregate amount of C$125,000 by the issuance of an aggregate number of 625,000 common shares of the Corporation (each a “Share”) at an issue price of C$0,20 per Share. The Corporation is proposing to issue the Shares in order to preserve its cash.</p> <p align="justify">The agreements http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html Thu, 18 Jun 2026 12:00:00 -0400 4D4A ADK DGNOF O.02535360 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html <p align="justify">BROSSARD, Quebec, June 18, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, announces its intention to settle two (2) arm’s-length demand loans in the aggregate amount of C$125,000 by the issuance of an aggregate number of 625,000 common shares of the Corporation (each a “Share”) at an issue price of C$0,20 per Share. The Corporation is proposing to issue the Shares in order to preserve its cash.</p> <p align="justify">The agreements http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html Thu, 18 Jun 2026 12:00:00 -0400 4D4A ADK DGNOF O.02535360 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html <p align="justify">BROSSARD, Quebec, June 18, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, announces its intention to settle two (2) arm’s-length demand loans in the aggregate amount of C$125,000 by the issuance of an aggregate number of 625,000 common shares of the Corporation (each a “Share”) at an issue price of C$0,20 per Share. The Corporation is proposing to issue the Shares in order to preserve its cash.</p> <p align="justify">The agreements http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html Thu, 18 Jun 2026 12:00:00 -0400 4D4A ADK DGNOF O.02535360 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html <p align="justify">BROSSARD, Quebec, June 18, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, announces its intention to settle two (2) arm’s-length demand loans in the aggregate amount of C$125,000 by the issuance of an aggregate number of 625,000 common shares of the Corporation (each a “Share”) at an issue price of C$0,20 per Share. The Corporation is proposing to issue the Shares in order to preserve its cash.</p> <p align="justify">The agreements http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html Thu, 18 Jun 2026 12:00:00 -0400 4D4A ADK DGNOF O.02535360 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html <p align="justify">BROSSARD, Quebec, June 18, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, announces its intention to settle two (2) arm’s-length demand loans in the aggregate amount of C$125,000 by the issuance of an aggregate number of 625,000 common shares of the Corporation (each a “Share”) at an issue price of C$0,20 per Share. The Corporation is proposing to issue the Shares in order to preserve its cash.</p> <p align="justify">The agreements http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Announces+Shares+for+Debt+Settlement/26664700.html Thu, 18 Jun 2026 12:00:00 -0400 4D4A ADK DGNOF O.02535360 http://www.streetinsider.com/Press+Releases/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html <p align="justify">BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada.</p> <p align="justify">Following detailed guidance from Health Canada in the fall of 2025, the Corporation&apos;s collaborative interactions have resulted in a comprehensive, advanced image analysis platform. The CARA System is designed to http://www.streetinsider.com/Press+Releases/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html Tue, 16 Jun 2026 09:15:00 -0400 4D4A A.17150087 ADK DGNOF O.02535360 O.34929518 http://www.streetinsider.com/Press+Releases/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html <p align="justify">BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada.</p> <p align="justify">Following detailed guidance from Health Canada in the fall of 2025, the Corporation&apos;s collaborative interactions have resulted in a comprehensive, advanced image analysis platform. The CARA System is designed to http://www.streetinsider.com/Press+Releases/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html Tue, 16 Jun 2026 09:15:00 -0400 4D4A A.17150087 ADK DGNOF O.02535360 O.34929518 http://www.streetinsider.com/Press+Releases/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html <p align="justify">BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada.</p> <p align="justify">Following detailed guidance from Health Canada in the fall of 2025, the Corporation&apos;s collaborative interactions have resulted in a comprehensive, advanced image analysis platform. The CARA System is designed to http://www.streetinsider.com/Press+Releases/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html Tue, 16 Jun 2026 09:15:00 -0400 4D4A A.17150087 ADK DGNOF O.02535360 O.34929518 http://www.streetinsider.com/Press+Releases/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html <p align="justify">BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada.</p> <p align="justify">Following detailed guidance from Health Canada in the fall of 2025, the Corporation&apos;s collaborative interactions have resulted in a comprehensive, advanced image analysis platform. The CARA System is designed to http://www.streetinsider.com/Press+Releases/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html Tue, 16 Jun 2026 09:15:00 -0400 4D4A A.17150087 ADK DGNOF O.02535360 O.34929518 http://www.streetinsider.com/Press+Releases/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html <p align="justify">BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada.</p> <p align="justify">Following detailed guidance from Health Canada in the fall of 2025, the Corporation&apos;s collaborative interactions have resulted in a comprehensive, advanced image analysis platform. The CARA System is designed to http://www.streetinsider.com/Press+Releases/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html Tue, 16 Jun 2026 09:15:00 -0400 4D4A A.17150087 ADK DGNOF O.02535360 O.34929518 http://www.streetinsider.com/Press+Releases/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html <p align="justify">BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada.</p> <p align="justify">Following detailed guidance from Health Canada in the fall of 2025, the Corporation&apos;s collaborative interactions have resulted in a comprehensive, advanced image analysis platform. The CARA System is designed to http://www.streetinsider.com/Press+Releases/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html Tue, 16 Jun 2026 09:15:00 -0400 4D4A A.17150087 ADK DGNOF O.02535360 O.34929518 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html <p align="justify">BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada.</p> <p align="justify">Following detailed guidance from Health Canada in the fall of 2025, the Corporation&apos;s collaborative interactions have resulted in a comprehensive, advanced image analysis platform. The CARA System is designed to http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html Tue, 16 Jun 2026 09:15:00 -0400 4D4A A.17150087 ADK DGNOF O.02535360 O.34929518 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html <p align="justify">BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada.</p> <p align="justify">Following detailed guidance from Health Canada in the fall of 2025, the Corporation&apos;s collaborative interactions have resulted in a comprehensive, advanced image analysis platform. The CARA System is designed to http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html Tue, 16 Jun 2026 09:15:00 -0400 4D4A A.17150087 ADK DGNOF O.02535360 O.34929518 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html <p align="justify">BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada.</p> <p align="justify">Following detailed guidance from Health Canada in the fall of 2025, the Corporation&apos;s collaborative interactions have resulted in a comprehensive, advanced image analysis platform. The CARA System is designed to http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html Tue, 16 Jun 2026 09:15:00 -0400 4D4A A.17150087 ADK DGNOF O.02535360 O.34929518 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html <p align="justify">BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada.</p> <p align="justify">Following detailed guidance from Health Canada in the fall of 2025, the Corporation&apos;s collaborative interactions have resulted in a comprehensive, advanced image analysis platform. The CARA System is designed to http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html Tue, 16 Jun 2026 09:15:00 -0400 4D4A A.17150087 ADK DGNOF O.02535360 O.34929518 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html <p align="justify">BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada.</p> <p align="justify">Following detailed guidance from Health Canada in the fall of 2025, the Corporation&apos;s collaborative interactions have resulted in a comprehensive, advanced image analysis platform. The CARA System is designed to http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html Tue, 16 Jun 2026 09:15:00 -0400 4D4A A.17150087 ADK DGNOF O.02535360 O.34929518 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html <p align="justify">BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada.</p> <p align="justify">Following detailed guidance from Health Canada in the fall of 2025, the Corporation&apos;s collaborative interactions have resulted in a comprehensive, advanced image analysis platform. The CARA System is designed to http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Submits+Modified+and+Updated+Health+Canada+Licence+Application+for+CARA+System+Platform/26651740.html Tue, 16 Jun 2026 09:15:00 -0400 4D4A A.17150087 ADK DGNOF O.02535360 O.34929518 http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Grant+of+Stock+Options+and+Adoption+of+Semi-Annual+Reporting/26640453.html <p align="justify">BROSSARD, Quebec, June 12, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, announces a grant of an aggregate number of 1,500,000 stock options to directors and officers of the Corporation.</p> <p align="justify">The date of the grant is June 11, 2026. The expiry date to which the stock options can be exercised is June 11, 2031. Stock options vest at 50% per year, commencing with the first anniversary of the grant. The exercise price http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Grant+of+Stock+Options+and+Adoption+of+Semi-Annual+Reporting/26640453.html Fri, 12 Jun 2026 15:50:00 -0400 4D4A ADK DGNOF O.02535360 http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Grant+of+Stock+Options+and+Adoption+of+Semi-Annual+Reporting/26640453.html <p align="justify">BROSSARD, Quebec, June 12, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, announces a grant of an aggregate number of 1,500,000 stock options to directors and officers of the Corporation.</p> <p align="justify">The date of the grant is June 11, 2026. The expiry date to which the stock options can be exercised is June 11, 2031. Stock options vest at 50% per year, commencing with the first anniversary of the grant. The exercise price http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Grant+of+Stock+Options+and+Adoption+of+Semi-Annual+Reporting/26640453.html Fri, 12 Jun 2026 15:50:00 -0400 4D4A ADK DGNOF O.02535360 http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Grant+of+Stock+Options+and+Adoption+of+Semi-Annual+Reporting/26640453.html <p align="justify">BROSSARD, Quebec, June 12, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, announces a grant of an aggregate number of 1,500,000 stock options to directors and officers of the Corporation.</p> <p align="justify">The date of the grant is June 11, 2026. The expiry date to which the stock options can be exercised is June 11, 2031. Stock options vest at 50% per year, commencing with the first anniversary of the grant. The exercise price http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Grant+of+Stock+Options+and+Adoption+of+Semi-Annual+Reporting/26640453.html Fri, 12 Jun 2026 15:50:00 -0400 4D4A ADK DGNOF O.02535360 http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Grant+of+Stock+Options+and+Adoption+of+Semi-Annual+Reporting/26640453.html <p align="justify">BROSSARD, Quebec, June 12, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, announces a grant of an aggregate number of 1,500,000 stock options to directors and officers of the Corporation.</p> <p align="justify">The date of the grant is June 11, 2026. The expiry date to which the stock options can be exercised is June 11, 2031. Stock options vest at 50% per year, commencing with the first anniversary of the grant. The exercise price http://www.streetinsider.com/Press+Releases/DIAGNOS+Announces+Grant+of+Stock+Options+and+Adoption+of+Semi-Annual+Reporting/26640453.html Fri, 12 Jun 2026 15:50:00 -0400 4D4A ADK DGNOF O.02535360 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Announces+Grant+of+Stock+Options+and+Adoption+of+Semi-Annual+Reporting/26640453.html <p align="justify">BROSSARD, Quebec, June 12, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, announces a grant of an aggregate number of 1,500,000 stock options to directors and officers of the Corporation.</p> <p align="justify">The date of the grant is June 11, 2026. The expiry date to which the stock options can be exercised is June 11, 2031. Stock options vest at 50% per year, commencing with the first anniversary of the grant. The exercise price http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Announces+Grant+of+Stock+Options+and+Adoption+of+Semi-Annual+Reporting/26640453.html Fri, 12 Jun 2026 15:50:00 -0400 4D4A ADK DGNOF O.02535360